DUSP1 and breast carcinoma: These results suggest that PRKCQ-AS1 induces tamoxifen resistance by upregulating MKP1 and activating MAPK/JNK pathway, which reduces tamoxifen treatment-induced apoptosis in ER + breast cancer cells.